Posted by Michael Wonder on 04 Jan 2022
Daratumumab in multiple myeloma: reassessment results in hint of considerable added benefit
3 January 2022 - Janssen applied for a new early benefit assessment due to new scientific findings.
The most recent data cut-off from the MAIA study now shows an advantage in overall survival.
